Q1 Earnings Estimate for enGene Issued By HC Wainwright

enGene Holdings Inc. (NASDAQ:ENGN) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of enGene in a research report issued on Monday, December 23rd. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings per share of ($0.41) for the quarter. HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for enGene’s current full-year earnings is ($1.52) per share. HC Wainwright also issued estimates for enGene’s Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.61) EPS, FY2026 earnings at ($1.57) EPS, FY2027 earnings at ($1.33) EPS, FY2028 earnings at ($0.38) EPS and FY2029 earnings at $0.37 EPS.

enGene (NASDAQ:ENGN) last released its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.06.

Other research analysts have also recently issued reports about the stock. Morgan Stanley reiterated an “overweight” rating and set a $40.00 price objective on shares of enGene in a report on Wednesday, September 11th. Oppenheimer reissued an “outperform” rating and set a $30.00 price objective on shares of enGene in a report on Tuesday, September 24th. Raymond James initiated coverage on enGene in a report on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 target price on the stock. Citizens Jmp upgraded enGene to a “strong-buy” rating in a report on Monday, November 18th. Finally, JMP Securities restated a “market outperform” rating and set a $18.00 price objective on shares of enGene in a research note on Monday. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $29.78.

enGene Stock Performance

Shares of ENGN stock opened at $6.32 on Wednesday. The company has a current ratio of 19.52, a quick ratio of 19.52 and a debt-to-equity ratio of 0.09. The firm has a fifty day simple moving average of $8.05 and a two-hundred day simple moving average of $7.77. enGene has a 12 month low of $4.42 and a 12 month high of $18.40. The firm has a market capitalization of $279.45 million, a PE ratio of -10.90 and a beta of -0.78.

Insider Activity

In other news, major shareholder Growth Opportunities F. Forbion acquired 341,332 shares of the company’s stock in a transaction that occurred on Monday, September 30th. The shares were acquired at an average price of $6.34 per share, for a total transaction of $2,164,044.88. Following the completion of the purchase, the insider now owns 2,400,791 shares in the company, valued at approximately $15,221,014.94. This trade represents a 16.57 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Ronald Harold Wilfred Cooper acquired 10,000 shares of enGene stock in a transaction on Friday, September 27th. The shares were purchased at an average cost of $5.70 per share, with a total value of $57,000.00. Following the completion of the acquisition, the chief executive officer now owns 10,000 shares of the company’s stock, valued at $57,000. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 420,965 shares of company stock valued at $2,651,103 in the last ninety days. 13.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Wolverine Asset Management LLC purchased a new stake in enGene in the 3rd quarter worth about $37,000. SR One Capital Management LP purchased a new stake in enGene during the second quarter valued at about $4,715,000. Point72 Asset Management L.P. boosted its position in enGene by 1,410.3% during the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock worth $4,376,000 after purchasing an additional 619,100 shares during the period. Franklin Resources Inc. increased its stake in shares of enGene by 48.7% in the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock worth $7,854,000 after purchasing an additional 389,918 shares in the last quarter. Finally, Logos Global Management LP raised its position in shares of enGene by 50.0% in the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after purchasing an additional 400,000 shares during the period. Hedge funds and other institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.